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A B S T R A C T   
Left Ventricular Noncompaction Cardiomyopathy (LVNC) is characterized by excessive trabeculation of the left ventricle. To date, mutations in more than 40 genes 
have been associated with LVNC, however the exact mechanisms underlying the disease remain unknown. Here, we describe an induced pluripotent stem cell (iPSC) 
line (UALGi001-A) from a LVNC patient (LVNC-iPSC) that does not present mutations in the genes most commonly associated with the disease (van Waning et al., 
2019). The LVNC-iPSC exhibited full pluripotency and differentiation potential, and retained a normal karyotype after reprogramming. This in vitro cellular model 
will be useful to study the molecular, genetic and functional aspects of LVNC.   
1. Resource Table:  
Unique stem cell line identifier UALGi001-A 
Alternative name(s) of stem cell 
line 
VITAL16 
Institution Universidade do Algarve, Faro, Portugal Algarve 
Biomedical Center Research Institute (ABC-RI), 
Faro, Portugal 
Contact information of 
distributor 
jebraganca@ualg.pt 
Type of cell line iPSC 
Origin Human 
Additional origin info required 




Cell Source Peripheral blood mononuclear cells 
Clonality Clonal 
Method of reprogramming Non-integrating, Sendai Virus expressing hOCT3/4, 
hSOX2, hKLF4 and hC-MYC 
Genetic Modification NO 
Type of Modification N/A 
Associated disease Left Ventricular Non-Compaction Cardiomyopathy 
(LVNC) 
Gene/locus N/A 
Date archived/stock date July 2020 
Cell line repository/bank https://hpscreg.eu/cell-line/UALGi001-A 
(continued on next column)  
(continued ) 
Unique stem cell line identifier UALGi001-A 
Ethical approval Approval ID: 78/19 by Ethics Committee for 
Health, Centro Hospital e Universitário do 
Algarve, Faro, Portugal  
2. Resource utility 
Left Ventricular Noncompaction Cardiomyopathy (LVNC) is a heart 
disorder characterized by endomyocardial noncompaction. UALGi001- 
A cell line, derived from a patient with LVNC offers a useful tool to 
study molecular and cellular mechanisms involved in this 
cardiomyopathy. 
3. Resource details 
Mononucleated cells were collected from 4 mL of peripheral blood 
sample from 75-year-old male. The patient was clinically diagnosed with 
left ventricular trabeculations located in the middle and apical segments 
and deep recesses, compatible with Left Ventricular Non-Compaction 
Cardiomyopathy (LVNC). LVNC is the third most prevalent heart mus-
cle disease, accounting for almost 10% of all cardiomyopathies and it is 
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characterized by the presence of a vast trabeculations likely due to 
endomyocardial morphogenesis arrest during embryogenesis (van 
Waning et al., 2019). LVNC clinical manifestations include heart failure, 
thromboembolism, ventricular arrhythmias, and ultimately sudden 
cardiac death (Finsterer et al., 2017). The human induced pluripotent 
stem cell (iPSC) line UALGi001-A was generated by using the Cyto-
Tune® iPSC-Reprogramming kit (Thermo Fisher Scientific, Invitrogen), 
encoding for the reprogramming factors hOCT3/4, hc-MYC, hKLF4, and 
hSOX2 (Takahashi and Yamanaka, 2006), according to manufacturer’s 
instructions. Clonal iPSC lines were established and further character-
ized (Table 1), formed colonies with a standard stem-like morphology 
visible by phase contrast, and were positive for Alkaline Phosphatase 
(AP) activity (Fig. 1A-B). The expression of pluripotency markers was 
demonstrated by immunofluorescence staining of SOX2, NANOG, OCT4 
and SSEA-4 (Fig. 1 C), as well as flow cytometry (Fig. 1D). Viral clear-
ance was confirmed at passage 14 (Supplementary Fig. S1A). 
Genomic integrity was assessed by karyotype analysis, showing that 
UALGi001-A, at passage 21, presented a normal diploid (46, XY) chro-
mosomal content (Fig. 1E). The capacity of iPSCs to differentiate into 
three germ layers was confirmed by embryoid body (EB) differentiation 
assay, and expression of ectoderm (TUJ1), endoderm (AFP) and meso-
derm (α-SMA) markers (Fig. 1F). DNA fingerprinting was used to prove 
the genetic identity to parental mononucleated blood cells (archived 
with journal). Mycoplasma was regularly tested negative throughout 
cell culture indicating that UALGi001-A line is mycoplasma-free (Sup-
plementary Fig. S1B). 
4. Materials and methods 
4.1. Reprogramming of PBMCs 
PBMCs were isolated using the Vacutainer® CPT™ tubes (BD Bio-
sciences). PBMCs were cultured (1.0 × 106 cells) in PBMCs Medium 
(StemPro-34 SFM medium; 1% GlutaMAX; 1% Pen/Strep, 100 ng/mL 
SCF, 100 ng/mL FLT-3; 20 ng/mL IL-3, 20 ng/mL 20 ng/mL IL-6; 25 ng/ 
mL GM-CSF), for one week before transduction with CytoTune®-iPS 2.0 
Sendai Reprogramming Kit. Briefly, 0.25 × 105 cells were transduced 
using MOI of 5–5-3 (hKOS, hc-MYC, hKLF4, respectively). After 24 h of 
incubation, cells were collected, centrifuged, and seeded in a 24-well 
plate containing PBMCs Medium. Two days later, cells were trans-
ferred onto a 6-well plate coated with Geltrex LDEV-Free Reduced 
Growth Factor Basement Membrane Matrix (Gibco) in ReproTeSR 
(STEMCELL Technologies), supplemented with 1% Pen/Strep. Individ-
ual colonies with stem-like morphology were manually isolated and 
expanded 14 to 21 days post-transduction. iPSC clones were cultured 
and expanded on 6-well plates coated with Geltrex LDEV-Free Reduced 
Growth Factor Basement Membrane Matrix, using a slip ratio of 1:5 and 
were maintained at 37 ◦C in humidified atmosphere containing 5% CO2. 
4.2. In vitro differentiation assay 
In vitro differentiation was performed by EB formation. iPSC col-
onies were lifted manually and cultured in non-adherent conditions in 
mTeSR1 medium, containing 0.4% of polyvinyl alcohol, for 48 h. 
Thereafter, the EBs were seeded on glass coverslips coated Geltrex 
LDEV-Free Reduced Growth Factor Basement Membrane Matrix and 
cultured for 3 weeks in differentiation medium (DMEM, 10% FBS, 1% 
Pen/Strep, 1% GlutaMAX, 1% MEM-NEAA). The coverslips were fixed 
with 4% paraformaldehyde (PFA) for 15 min and analyzed by immu-
nofluorescence (Table 2) on Axioimager Z2/Apotome fluorescence mi-
croscope (Carl Zeiss). 
4.3. Immunocytochemistry 
Cells were allowed to grow in glass coverslips coated with Geltrex 
LDEV-Free Reduced Growth Factor Basement Membrane Matrix and 
washed in ice-cold PBS before fixation in 4% PFA, for 15 min. Fixed cells 
were washed twice in PBS and placed in blocking solution (2% bovine 
serum albumin in 0.2% Triton-X100/PBS) for 1 h, at room temperature. 
Cells were incubated for 1 h at room temperature with the primary 
antibody (Table 2). After incubation, samples were washed 3 times with 
0.2% Triton X100/PBS, and incubated with the secondary antibodies for 
1 h, at room temperature (Table 2). After 3 washes, sections were 
mounted with Fluoromount G mounting medium (Thermo Fisher Sci-
entific) containing 4,6-diamidino-2-phenylindole (DAPI) and analyzed 
on a Axioimager Z2 fluorescence microscope (Carl Zeiss) 
4.4. Flow cytometry 
iPSCs were dissociated using TrypLE Select (Gibco) for 3 min at RT, 
centrifuged at 300 g for 5 min and 100,000 cells resuspended in 200 μl of 
ice-cold 0.5 % PFA in PBS, for 20 min. Fixed cells were washed twice in 
PBS/0.5% BSA/0.1% Triton X100 and incubated with the primary 
antibody for 1 h at 4 ◦C (Table 2). After incubation, samples were 
washed 3 times with PBS/0.5% BSA/0.1% Triton X100, and incubated 
with the secondary antibodies for 1 h, at 4 ◦C (Table 2), protected from 
light. The cells were analyzed using a FACScalibur cell analyzer (BD 
Biosciences) and data was analyzed by CytExpert 2.0 software. 
4.5. Alkaline phosphatase activity 
Alkaline phosphatase staining was carried out using Alkaline Phos-
phatase Staining Kit II (Stemgent, MA). 
Table 1 
Characterization and validation.  
Classification Test Result Data 
Morphology Photography Bright 
field 
Normal Fig. 1A 







Sox2, and SSEA- 
4 





cells: 95%; SSEA- 
4 positive cells: 
93,3% 
Fig. 1D 





Identity Microsatellite PCR 
(mPCR) 
Not performed N/A 







Sequencing N/A N/A 






















HIV 1 + 2 Hepatitis B, 
Hepatitis C 







Not performed N/A 
HLA tissue typing Not performed N/A  
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4.6. Karyotype analyses 
Genome integrity of the iPSC was evaluated by G-banding at 
400–550 band resolution, with a minimum of 30 metaphase spreads 
analyzed (Genomed, Lisbon, Portugal). 
4.7. RT-PCR for detection of viral clearance 
Total RNA was isolated from cultured iPSC with RNeasy Mini Kit 
(Qiagen). 1 μg of total RNA was used as template to obtain cDNA, using 
NZY First-Strand cDNA Synthesis Kit (nzytech). Viral clearance was 
Fig. 1. Characterisation of the induced pluripotent stem cell line (UALGi001-A) from a patient with LVNC. (A) Phase contrast micrograph of UALGi001-A colony 
cultured in feeder-free conditions. (B) Alkaline phosphatase positive staining. CC) Flow cytometry of nuclear (NANOG) and surface (SSEA-4) pluripotency markers. 
(D) Immunofluorescence for pluripotency markers OCT4, SOX2, NANOG, and SSEA-4. Nuclei were counterstained with DAPI (blue). (E) Representative metaphase 
showing normal diploid 46, XY karyotype. (F) Immunocytochemistry for ectodermal (TUJ1), endodermal (AFP) and mesodermal (αSMA) markers. Nuclei were 
counterstained with DAPI (blue). 
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analyzed using the primers described in Table 2. RT-PCR reaction was 
performed using DreamTaq DNA Polymerase (Thermo Scientific) and 
PCR products were visualized on a 2% agarose gel. 
4.8. Fingerprinting 
Genomic DNA from PBMC and iPSC was extracted using QIAamp 
DNA Blood mini kit (Qiagen). Fingerprinting analyses was performed 
using Promega’s PowerPlex 16 kit and analyzed on ABI PRISM 3100 
using GeneMapper (Thermo Fisher) by STABVida, Lisbon, Portugal. 
4.9. Mycoplasma detection 
The presence of mycoplasma was tested regularly by PCR (Uphoff 
and Drexler, 2001) using the Primers listed in Table 2. 
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Supplementary data to this article can be found online at https://doi. 
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Table 2 
Reagents details.   
Antibodies used for immunocytochemistry/flow-cytometry 
Antibody Dilution Company Cat # RRID 








Cell Signaling Technology Cat# 2840 
Cell Signaling Technology Cat# 4903 
Cell Signaling Technology Cat# 3579 

















Secondary antibodies for immunofluorescence Donkey anti-Mouse 488 
Donkey anti-Rabbit 594 
1:500 
1:500 
Molecular Probes Cat# A-21202 
Molecular Probes Cat# A-21207 
RRID: AB_141607 
RRID: AB_141637 
Secondary antibodies for flow cytometry Donkey anti-Rabbit 488 1:200 Molecular Probes Cat# A-21206 RRID: AB_2535792  
Primers  
Target Size of band Forward/Reverse primer (5′-3′) 






















500 bp Forward primers: 
CGC CTG AGT AGT ACG TTC GC 
CGC CTG AGT AGT ACG TAC GC 
TGC CTG AGT AGT ACA TTC GC 
CGC CTG GGT AGT ACA TTC GC 
CGC CTG AGT AGT ATG CTC GCTGC CTG GGT AGT ACA TTC GC  
Reverse primers: 
GCG GTG TGT ACA AGA CCC GA 
GCG GTG TGT ACA AAA CCC GA 
GCG GTG TGT ACA AAC CCC GA  
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